TY - JOUR
T1 - Novel tumor-promoting property of tamoxifen
AU - Zhong, M.
AU - Lu, Z.
AU - Abbas, T.
AU - Hornia, A.
AU - Chatakondu, K.
AU - Barile, N.
AU - Kaplan, P.
AU - Foster, D. A.
PY - 2001
Y1 - 2001
N2 - The tumor-promoting phorbol ester TPA (12-O-tetradecanoylphorbol-13-acetate) cooperates with c-Src overexpression to transform rat fibroblasts. TPA transforms c-Src-overexpressing cells by depleting the δ isoform of protein kinase C (PKCδ), Tamoxifen, which has both estrogen-mimetic and estrogen-antagonist properties, has been widely used to improve the prognosis of breast cancer patients. However, with extended use, there is an increased risk for endometrial and other cancers that can be observed within 10 years of treatment. We report here that tamoxifen, similar to TPA, cooperates with c-Src overexpression to transform 3Y1 rat fibroblasts. Tamoxifen induced both DNA synthesis and anchorage-independent cell proliferation in c-Src-overexpressing, but not in parental, 3Y1 rat fibroblasts. Tamoxifen also induced an association between c-Src and PKCδ that resulted in the tyrosine phosphorylation and down-regulation of PKCδ. These phenotypes were not induced by estrogen, indicating that the effect of tamoxifen was in addition to any estrogen-mimetic effects. Thus, in addition to the hyperplasia-inducing capability of an estrogen-mimetic, tamoxifen has an additional tumor-promoting capability similar to that of TPA. The dual tumor-promoting capability of both estrogen- and TPA-mimetic properties for tamoxifen may contribute to the increased incidence of endometrial cancers observed in the relatively short exposure period of <10 years.
AB - The tumor-promoting phorbol ester TPA (12-O-tetradecanoylphorbol-13-acetate) cooperates with c-Src overexpression to transform rat fibroblasts. TPA transforms c-Src-overexpressing cells by depleting the δ isoform of protein kinase C (PKCδ), Tamoxifen, which has both estrogen-mimetic and estrogen-antagonist properties, has been widely used to improve the prognosis of breast cancer patients. However, with extended use, there is an increased risk for endometrial and other cancers that can be observed within 10 years of treatment. We report here that tamoxifen, similar to TPA, cooperates with c-Src overexpression to transform 3Y1 rat fibroblasts. Tamoxifen induced both DNA synthesis and anchorage-independent cell proliferation in c-Src-overexpressing, but not in parental, 3Y1 rat fibroblasts. Tamoxifen also induced an association between c-Src and PKCδ that resulted in the tyrosine phosphorylation and down-regulation of PKCδ. These phenotypes were not induced by estrogen, indicating that the effect of tamoxifen was in addition to any estrogen-mimetic effects. Thus, in addition to the hyperplasia-inducing capability of an estrogen-mimetic, tamoxifen has an additional tumor-promoting capability similar to that of TPA. The dual tumor-promoting capability of both estrogen- and TPA-mimetic properties for tamoxifen may contribute to the increased incidence of endometrial cancers observed in the relatively short exposure period of <10 years.
UR - http://www.scopus.com/inward/record.url?scp=0034928221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034928221&partnerID=8YFLogxK
M3 - Article
C2 - 11331247
AN - SCOPUS:0034928221
SN - 1044-9523
VL - 12
SP - 187
EP - 192
JO - Cell Growth and Differentiation
JF - Cell Growth and Differentiation
IS - 4
ER -
